Market Place
Sourcing Support
Oncoinvent ASA announces oversubscribed private placement
05 Dec 2024 //
PR NEWSWIRE
Oncoinvent & ARTBIO To Collaborate On Radiopharma Lab Facilities
04 Dec 2024 //
BUSINESSWIRE
Oncoinvent Announces Positive Results for Radspherin in Carcinomatosis
11 Nov 2024 //
BUSINESSWIRE
Oncoinvent to Present at JonesTrading Virtual Radiopharma Day
28 Oct 2024 //
BUSINESSWIRE
Oncoinvent Doses First Patient In Radspherin Ovarian Cancer Trial
10 Oct 2024 //
BUSINESSWIRE
Oncoinvent Appoints Oystein Soug as CEO
28 Aug 2024 //
BUSINESSWIRE
Oncoinvent Receives FDA Fast Track for Radspherin for Ovarian Cancer
27 Jun 2024 //
PHARMABIZ
Oncoinvent receives FDA Fast Track Designation for Radspherin in carcinomatosis.
24 Jun 2024 //
BUSINESSWIRE
Oncoinvent To Present At Cantor Radiopharma Summit
15 May 2024 //
BUSINESSWIRE
Oncoinvent Announces Changes to its BODs and Clinical Advisory Board
02 Apr 2024 //
BUSINESSWIRE
Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference
21 Feb 2024 //
BUSINESSWIRE
Oncoinvent Announces U.S. FDA Clearance of IND Application for Radspherin
31 Oct 2023 //
BUSINESSWIRE
Oncoinvent Announces U.S. FDA Clearance of IND Application for Radspherin
27 Oct 2023 //
BUSINESSWIRE
Oncoinvent Presents 18-Month Safety and Efficacy Data from Ongoing RAD-18-002
04 Oct 2023 //
BUSINESSWIRE
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin
28 Sep 2023 //
BUSINESSWIRE
Oncoinvent appoints Anders Månsson as CEO
05 Jul 2023 //
BUSINESSWIRE
Oncoinvent to Present at TD Cowen Radiopharmaceutical Innovation Summit
16 Jun 2023 //
BUSINESSWIRE
Oncoinvent Presents Safety Data from RAD-18-002 Phase 1/2A Trial of Radspherin
05 Jun 2023 //
BUSINESSWIRE
Oncoinvent Announces Two Publications in Special Edition of Frontiers Medicine
21 Apr 2023 //
BUSINESSWIRE
Oncoinvent Initiates Radspherin Phase 2A Trial
25 Aug 2022 //
BUSINESSWIRE
Data From the Ongoing Radspherin RAD-18-002 Phase 1 Trial in Colorectal Cancer
26 May 2022 //
BUSINESSWIRE
Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day
10 May 2022 //
BUSINESSWIRE
Oncoinvent to Participate in Upcoming Virtual Investor Conferences
15 Feb 2022 //
BUSINESSWIRE
Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors
04 Feb 2022 //
BUSINESSWIRE
Oncoinvent Completes Enrollment in RAD-18-002 Phase 1 Clinical Study
08 Nov 2021 //
BUSINESSWIRE
Oncoinvent to Present Four Posters at the 34th Annual Congress of the European
20 Oct 2021 //
BUSINESSWIRE
Oncoinvent Announces Advancement of Radspherin to Fourth Dose Level Cohort
28 Sep 2021 //
BUSINESSWIRE
Oncoinvent`s Radspherin® to 3rd Dose Level Cohort in Ongoing RAD-18-001 Ph1
08 Mar 2021 //
BUSINESSWIRE
